keyword
MENU ▼
Read by QxMD icon Read
search

Zoledronic acid

keyword
https://www.readbyqxmd.com/read/28094562/effects-of-bisphosphonate-administration-on-cleft-bone-graft-in-a-rat-model
#1
Nicole Cheng, Juyoung Park, Jeffrey Olson, Taewoo Kwon, Deborah Lee, Rachel Lim, Sandy Ha, Reuben Kim, Xinli Zhang, Kang Ting, Sotirios Tetradis, Christine Hong
OBJECTIVE:   Bone grafts in patients with cleft lip and palate can undergo a significant amount of resorption. The aim of this study was to investigate the effects of bisphosphonates (BPs) on the success of bone grafts in rats. DESIGN:   Thirty-five female 15-week-old Fischer F344 Inbred rats were divided into the following experimental groups, each receiving bone grafts to repair an intraoral CSD: (1) Graft/saline: systemic administration of saline and (2) systemic administration of zoledronic acid immediately following surgery (graft/BP/T0), (3) 1 week postoperatively (graft/BP/T1), and (4) 3 weeks postoperatively (graft/BP/T2)...
January 17, 2017: Cleft Palate-craniofacial Journal
https://www.readbyqxmd.com/read/28089632/long-interval-zoledronic-acid-use-in-bone-metastases
#2
Manjulika Das
No abstract text is available yet for this article.
January 12, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28074765/-osteoporosis-treatment-can-be-discontinued-based-on-an-individual-assessment
#3
Pia A Eiken, Bo Abrahamsen
In most patients, treatment of osteoporosis is a long-term challenge. Because alendronate and zoledronic acid accumulate in bone with some persistent antifracture efficacy after therapy, it is reasonable to consider a "drug holiday" for low-risk patients. It is recommended that the duration and length of drug holiday should be individualized for each patient. For all other bisphosphonates data are limited. For other antiresorptive and anabolic agents "drug holiday" is not recommended.
January 9, 2017: Ugeskrift for Laeger
https://www.readbyqxmd.com/read/28068876/tissue-engineered-model-of-human-osteolytic-bone-tumor
#4
Aranzazu Villasante, Alessandro Marturano, Samuel T Robinson, Zen Liu, X Edward Guo, Gordana Vunjak-Novakovic
Ewing's sarcoma (ES) is a poorly differentiated pediatric tumor of aggressive behavior characterized by propensity to metastasize to bone. Interactions between the tumor and bone cells orchestrate a vicious cycle in which tumor cells induce osteoclast differentiation and activation to cause osteolytic lesions, broken bones, pain and hypercalcemia. The lack of controllable models that can recapitulate osteolysis in ES impedes the development of new therapies and limits our understanding of how tumor cells invade bone...
January 9, 2017: Tissue Engineering. Part C, Methods
https://www.readbyqxmd.com/read/28058444/frequency-of-discontinuation-of-injectable-osteoporosis-therapies-in-us-patients-over-2%C3%A2-years
#5
A Modi, S Sajjan, R Insinga, J Weaver, E M Lewiecki, S T Harris
: Little is known about treatment patterns with injectable osteoporosis therapies. At 12 months, the probability of discontinuation was 69.1% among patients using ibandronate, followed by teriparatide (67.1%), zoledronic acid (59.2%), and denosumab (48.8%). By 24 months, discontinuation was higher for each treatment. The majority of US patients discontinue injectable osteoporosis treatment by the end of the first year following initiation. INTRODUCTION: This study was designed to assess the frequency of treatment discontinuation over time among patients who initiate injectable osteoporosis therapies...
January 5, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28054399/comparison-of-effects-of-zoledronic-acid-and-clodronate-on-the-bone-structure-imaginological-and-histomorphometrical-study-in-vivo
#6
Stephanie Joana Roman Martelli, Melissa Feres Damian, Ana Paula Neutzling Gomes, André Ribeiro Schinestsck, Alexandre Emídio Ribeiro Silva, Ana Carolina Uchoa Vasconcelos
OBJECTIVES: To compare histologically and imaginologically the bone structure of rats' mandibles treated with bisphosphonates (BPs) and rats that did not receive BPs. METHODS: Thirty-four rat specimens (Rattus novergicus, Wistar strain) were divided in 3 groups: (1) 12 rats treated with zoledronic acid; (2) 12 rats treated with clodronate; and (3) the control group, containing 10 rats that received saline solution. All individuals were exposed to cone beam computed tomography (CBCT)...
January 5, 2017: Journal of Oral Pathology & Medicine
https://www.readbyqxmd.com/read/28039445/aromatase-inhibitor-induced-bone-loss-increases-the-progression-of-estrogen-receptor-negative-breast-cancer-in-bone-and-exacerbates-muscle-weakness-in-vivo
#7
Laura E Wright, Ahmed A Harhash, Wende M Kozlow, David L Waning, Jenna N Regan, Yun She, Sutha K John, Sreemala Murthy, Maryla Niewolna, Andrew R Marks, Khalid S Mohammad, Theresa A Guise
Aromatase inhibitors (AIs) cause muscle weakness, bone loss, and joint pain in up to half of cancer patients. Preclinical studies have demonstrated that increased osteoclastic bone resorption can impair muscle contractility and prime the bone microenvironment to accelerate metastatic growth. We hypothesized that AI-induced bone loss could increase breast cancer progression in bone and exacerbate muscle weakness associated with bone metastases. Female athymic nude mice underwent ovariectomy (OVX) or sham surgery and were treated with vehicle or AI (letrozole; Let)...
December 25, 2016: Oncotarget
https://www.readbyqxmd.com/read/28035539/brucine-inhibits-bone-metastasis-of-breast-cancer-cells-by-suppressing-jagged1-notch1-signaling-pathways
#8
Ke-Fei Hu, Xiang-Ying Kong, Mi-Cun Zhong, Hong-Ye Wan, Na Lin, Xiao-Hua Pei
OBJECTIVE: To examine the effects of brucine on the invasion, migration and bone resorption of receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoclastogenesis. METHODS: The osteoclastogenesis model was builded by co-culturing human breast tumor MDA-MB-231 and mouse RAW264.7 macrophages cells. RANKL (50 ng/mL) and macrophage-colony stimulating factor (50 ng/mL) were added to this system, followed by treatment with brucine (0.02, 0.04 and 0...
December 29, 2016: Chinese Journal of Integrative Medicine
https://www.readbyqxmd.com/read/28035364/cyr61-ccn1-stimulates-proliferation-and-differentiation-of-osteoblasts-in-vitro-and-contributes-to-bone-remodeling-in-vivo-in-myeloma-bone-disease
#9
Hui Liu, Fengping Peng, Zhaoyun Liu, Fengjuan Jiang, Lijuan Li, Shan Gao, Guojin Wang, Jia Song, Erbao Ruan, Zonghong Shao, Rong Fu
Cysteine-rich 61 (CYR61/CCN1), a secreted protein in bone marrow (BM) microenvironment, has diverse effects on many cellular activities such as growth and differentiation. However, the effect of CCN1 on osteoblasts (OBs) in myeloma bone disease remains unclear. In our study, the level of CCN1 in multiple myeloma (MM) patients was detected by ELISA and RT-PCR. The proliferation and differentiation of OBs from MM patients were observed after stimulated by CCN1 in vitro. The myeloma cells transduced with CYR61 gene (RPMI‑8226/CYR61) were injected in a mouse model to evaluate the efficacy of CCN1 in vivo and compare with zoledronic acid...
February 2017: International Journal of Oncology
https://www.readbyqxmd.com/read/28030702/effect-of-longer-interval-vs-standard-dosing-of-zoledronic-acid-on-skeletal-events-in-patients-with-bone-metastases-a-randomized-clinical-trial
#10
Andrew L Himelstein, Jared C Foster, James L Khatcheressian, John D Roberts, Drew K Seisler, Paul J Novotny, Rui Qin, Ronald S Go, Stephen S Grubbs, Tracey O'Connor, Mario R Velasco, Douglas Weckstein, Ann O'Mara, Charles L Loprinzi, Charles L Shapiro
Importance: Zoledronic acid, a third-generation aminobisphosphonate, reduces the incidence of skeletal-related events and pain in patients with bone metastases. The optimal dosing interval for zoledronic acid is uncertain. Objective: To determine whether zoledronic acid administered every 12 weeks is noninferior to zoledronic acid administered every 4 weeks. Design, Setting, Participants: Randomized, open-label clinical trial conducted at 269 academic and community sites in the United States...
3, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28009424/addition-of-docetaxel-and-or-zoledronic-acid-to-standard-of-care-for-hormone-naive-prostate-cancer-a-cost-effectiveness-analysis
#11
Pengfei Zhang, Feng Wen, Ping Fu, Yu Yang, Qiu Li
BACKGROUND: The effectiveness of the addition of docetaxel and/or zoledronic acid to the standard of care (SOC) for hormone-naive prostate cancer has been evaluated in the STAMPEDE trial. The object of the present analysis was to evaluate the cost-effectiveness of these treatment options in the treatment of advanced hormone-naive prostate cancer in China. METHODS: A cost-effectiveness analysis using a Markov model was carried out from the Chinese societal perspective...
November 22, 2016: Tumori
https://www.readbyqxmd.com/read/28000034/safety-pharmacokinetics-and-changes-in-bone-metabolism-associated-with-zoledronic-acid-treatment-in-japanese-patients-with-primary-osteoporosis
#12
Masataka Shiraki, Satoshi Tanaka, Hiroaki Suzuki, Satoko Ueda, Toshitaka Nakamura
Although once-yearly intravenous administration of zoledronic acid has been reported to inhibit bone resorption and increase bone mineral density, no studies have evaluated its effectiveness in treating osteoporosis in Japanese patients. Therefore, the purpose of this study was to investigate the pharmacokinetics and assess the safety of and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis. This was a single-administration study with a single-blind parallel-group design...
December 20, 2016: Journal of Bone and Mineral Metabolism
https://www.readbyqxmd.com/read/27987763/novel-therapeutic-intervention-for-osteoporosis-prepared-with-strontium-hydroxyapatite-and-zoledronic-acid-in-vitro-and-pharmacodynamic-evaluation
#13
Deepak Kumar Khajuria, Ramakrishna Vasireddi, Martin Trebbin, David Karasik, Rema Razdan
Osteoporosis therapeutics has been monopolized mainly by bisphosphonates, which are potent anti-osteoporotic drugs, while they do not promote bone formation or replenish the already resorbed bone. Although strontium substituted hydroxyapatite (SrHA) has been proclaimed to improve bone properties in an osteoporotic animal model, there is no published data on direct delivery of SrHA nanoparticles by bisphosphonate-like zoledronic acid (ZOL) to the bone. Therefore, this study was designed to investigate the potential of using SrHA/ZOL nanoparticle-based drug formulation in an ovariectomized rat model of postmenopausal osteoporosis...
February 1, 2017: Materials Science & Engineering. C, Materials for Biological Applications
https://www.readbyqxmd.com/read/27984143/delineating-residues-for-haemolytic-activities-of-snake-venom-cardiotoxin-1-from-naja-naja-as-probed-by-molecular-dynamics-simulations-and-in-vitro-validations
#14
Biswajit Gorai, Thirunavukkarasu Sivaraman
Cardiotoxins (CTXs) are single polypeptide chain consisting of 59-62 amino acids with four disulfide bridges and globular proteins of simple β-sheet folds. The CTXs are one of principal toxic components causing haemolysis and damaging various cells and belong to three-finger toxin (TFT) superfamily of snake venoms. However, there is no natural or synthetic small molecular inhibitor to the protein toxins to date. In the present study, modes of interaction of cardiotoxin 1 (CTX1) from Indian cobra (Naja naja) with heterogeneous erythrocyte membrane (EM) model system have been extensively examined by using all-atom molecular dynamics (MD) simulations in near physiological conditions and comprehensive analyses of the MD data revealed two distinct principal regions ('head groove' and 'loop groove') of the protein toxin for establishing structural interactions with the EM system...
February 2017: International Journal of Biological Macromolecules
https://www.readbyqxmd.com/read/27982227/effects-of-zoledronic-acid-on-orthodontic-tooth-movement-in-rats
#15
Marcel Durante Brunet, Cristiano Miranda de Araujo, Aline Cristina Batista Rodrigues Johann, Elisa Souza Camargo, Orlando Motohiro Tanaka, Odilon Guariza
The purpose of this study was to assess the effects of the administration of zoledronic acid (ZA) during orthodontic movement in rats. A hundred and twenty male Wistar rats were applied force of 30 cN with spring closed nickel-titanium to move the upper right first molar to mesial. In the Control Movement group (CM), only tooth movement was performed; the Control Acid Zoledronic group (CAZ) received a single dose (0.1 mg/kg) of ZA; the Experimental Acid Zoledronic group (EAZ) received a single dose (0.1 mg/kg) one week prior to the start of tooth movement; and the Control Without movement group (CWM) that received no drug and without application of tooth movement...
September 2016: Brazilian Dental Journal
https://www.readbyqxmd.com/read/27980244/a-clinical-study-on-administration-of-opioid-antagonists-in-terminal-cancer-patients
#16
Yoshihiro Uekuzu, Takashi Higashiguchi, Akihiko Futamura, Akihiro Ito, Naoharu Mori, Miyo Murai, Hiroshi Ohara, Hiroko Awa, Takeshi Chihara
There have been few detailed reports on respiratory depression due to overdoses of opioids in terminal cancer patients. We investigated the situation of treatment with opioid antagonists for respiratory depression that occurred after administration of opioid at optimal doses in terminal cancer patients, to clarify pathological changes as well as causative factors. In 2,443 terminal cancer patients receiving opioids, 7 patients (0.3%) received opioid antagonists: 6, morphine (hydrochloride, 5; sulfate, 1); 1, oxycodone...
December 16, 2016: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/27979458/zoledronic-acid-in-first-line-treatment-of-prostate-cancer
#17
Michael Pinkawa
No abstract text is available yet for this article.
January 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27977859/immune-cell-profile-of-dental-pulp-tissue-treated-with-zoledronic-acid
#18
P G de Barros Silva, M E Q L Verde, L A C Brizeno, D V T Wong, R C P Lima Júnior, F B Sousa, M R L Mota, A P N N Alves
AIM: To characterize the pulp immune cell profile in the teeth of rats treated with zoledronic acid (ZA). METHODOLOGY: Male Wistar rats (n = 6 per group) received four intravenous infusions of ZA at doses of 0.04, 0.20 or 1.00 mg kg(-1) ZA or saline (control). On the 70th experimental day, they were euthanized. The first right molar was examined microscopically and submitted to toluidine blue reaction and immunohistochemical for CD68, tumour necrosis Factor (TNF)-α, interleukin (IL)-1β, inducible nitric oxide synthase (iNOS), nuclear factor kappa B (NF-kB) and IL-18 binding protein (IL-18 bp)...
December 15, 2016: International Endodontic Journal
https://www.readbyqxmd.com/read/27971474/cost-effectiveness-analysis-of-once-yearly-injection-of-zoledronic-acid-for-the-treatment-of-osteoporosis-in-japan
#19
K Moriwaki, M Mouri, H Hagino
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27966106/retreatment-with-teriparatide-our-experience-in-three-patients-with-severe-secondary-osteoporosis
#20
D L Mana, M B Zanchetta, J R Zanchetta
Teriparatide is a drug for the treatment of osteoporosis which is licensed for use for up to 24 months. There is little experience with retreatment. The aim of this study was to evaluate, in three patients with severe secondary osteoporosis, the response to a second cycle of teriparatide regarding bone mineral density (BMD) and osteocalcin. Case 1 : A 62-year-old woman with multiple vertebral fractures has received corticoids for a long time. After starting teriparatide, her BMD and osteocalcin increased. She then received ibandronate for 3 years but her BMD declined...
December 14, 2016: Osteoporosis International
keyword
keyword
27337
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"